Biodexa Historical Cash Flow
| BDRX Stock | 1.23 0.06 4.65% |
Analysis of Biodexa Pharmaceticals cash flow over time is an excellent tool to project Biodexa Pharmaceticals future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 242 K or Other Non Cash Items of 603.6 K as it is a great indicator of Biodexa Pharmaceticals ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Biodexa Pharmaceticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Biodexa Pharmaceticals is a good buy for the upcoming year.
Biodexa |
About Biodexa Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Biodexa balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Biodexa's non-liquid assets can be easily converted into cash.
Biodexa Pharmaceticals Cash Flow Chart
Add Fundamental
Capital Expenditures
Capital Expenditures are funds used by Biodexa Pharmaceticals to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Biodexa Pharmaceticals operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Most accounts from Biodexa Pharmaceticals' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Biodexa Pharmaceticals current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biodexa Pharmaceticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Biodexa Stock please use our How to Invest in Biodexa Pharmaceticals guide.At this time, Biodexa Pharmaceticals' Change In Cash is fairly stable compared to the past year. Other Non Cash Items is likely to rise to about 603.6 K in 2025, whereas Free Cash Flow is likely to drop (6.7 M) in 2025.
| 2022 | 2023 | 2024 | 2025 (projected) | Begin Period Cash Flow | 10.1M | 2.8M | 2.6M | 2.4M | End Period Cash Flow | 2.8M | 6.0M | 5.4M | 8.0M |
Biodexa Pharmaceticals cash flow statement Correlations
Click cells to compare fundamentals
Biodexa Pharmaceticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Biodexa Pharmaceticals cash flow statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | (3.4M) | 2.5M | (7.2M) | 3.1M | 2.8M | 3.0M | |
| Free Cash Flow | (9.5M) | (6.3M) | (7.1M) | (7.1M) | (6.4M) | (6.7M) | |
| Change In Working Capital | (1.6M) | (617K) | 520K | (49K) | (56.4K) | (59.2K) | |
| Other Cashflows From Financing Activities | (476K) | (15K) | (18K) | (13K) | (11.7K) | (11.1K) | |
| Depreciation | 1.2M | 403K | 343K | 283K | 254.7K | 242.0K | |
| Other Non Cash Items | 430K | (892K) | 454K | 397K | 357.3K | 603.6K | |
| Capital Expenditures | 209K | 320K | 62K | 263K | 236.7K | 380.6K | |
| Total Cash From Operating Activities | (9.3M) | (6.0M) | (7.0M) | (6.8M) | (6.1M) | (6.5M) | |
| Change To Account Receivables | 493K | (487K) | 7K | 365K | 419.8K | 440.7K | |
| Net Income | (22.2M) | (5.5M) | (7.7M) | (7.1M) | (6.4M) | (6.7M) | |
| Total Cash From Financing Activities | 3.1M | 8.8M | 47K | 10.2M | 9.2M | 6.7M | |
| End Period Cash Flow | 7.5M | 10.1M | 2.8M | 6.0M | 5.4M | 8.0M | |
| Begin Period Cash Flow | 10.9M | 7.5M | 10.1M | 2.8M | 2.6M | 2.4M | |
| Stock Based Compensation | (404K) | 89K | 123K | 28K | 32.2K | 33.8K | |
| Investments | 2.6M | (278K) | (220K) | (265K) | (304.8K) | (320.0K) | |
| Issuance Of Capital Stock | 9.7M | 9.0M | 243K | 10.4M | 9.4M | 7.0M | |
| Other Cashflows From Investing Activities | 144K | 42K | (158K) | (239K) | (274.9K) | (288.6K) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Biodexa Stock Analysis
When running Biodexa Pharmaceticals' price analysis, check to measure Biodexa Pharmaceticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biodexa Pharmaceticals is operating at the current time. Most of Biodexa Pharmaceticals' value examination focuses on studying past and present price action to predict the probability of Biodexa Pharmaceticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biodexa Pharmaceticals' price. Additionally, you may evaluate how the addition of Biodexa Pharmaceticals to your portfolios can decrease your overall portfolio volatility.